Why this matters now
The next two years of biotech will be decided less by laboratory results than by who can afford to wait for them. On 30 October 2026 a $1 trillion tech selloff deepened fears of an AI bubble, and the Nasdaq 100 had its worst day since June.1 The next day OpenAI cut its funding target by $10 billion.2 On 1 November, Binance users withdrew $3.6 billion when the exchange reopened after a hack.3 None of these events involves a drug. But companies that sell no products live on money raised from investors, and when risk appetite shrinks, that money costs more or stops arriving.
A caution on scale: the dossier behind this piece gives no comparison that would let us say what $1 trillion is relative to, say, the whole biotech sector, so we will not invent one. We can say only that the selloff was large enough to be reported as the worst day for the Nasdaq 100 in months.
What a strong balance sheet looks like: Incyte
The clearest verified data in our files comes from Incyte Corporation, a Wilmington, Delaware drug company that develops Jakafi, Opzelura and pemigatinib.4 Its cash, as filed with the US Securities and Exchange Commission, tells a story of swings rather than a straight line. At the end of fiscal 2023 Incyte held about $3.21 billion.5 By mid-2024 that had fallen to about $987 million (second quarter 2024), and the year closed at about $1.69 billion.6 Then it rebuilt: about $3.10 billion at the end of fiscal 2025,7 about $3.46 billion in the first quarter of 2026,8 and about $3.98 billion in the second quarter of 2026.9 The most recent filing, for the third quarter of 2026, shows about $3.28 billion, lower than the quarter before but still well above the 2024 low.10
Our files do not say why cash moved in each period, so we do not offer reasons. What the numbers do show is that even an established company with marketed drugs saw its cash fall to under a third of its 2023 level within a year and then recover. A pre-revenue company has no such recovery mechanism except new investors.
Other verified figures put that cash in context. Incyte's cost of revenue, the direct cost of the products it sells, was about $255 million in fiscal 2023, $312 million in fiscal 2024 and $372 million in fiscal 2025.11 Its earnings were $2.65 per share in fiscal 2023.12 Capital expenditure, money spent on equipment and facilities, was recorded at $48.7 million in both fiscal 2024 and fiscal 2025.13 Identical figures in consecutive years are possible but unusual, and we flag them for readers who want to check the filings themselves.
The smaller companies: milestones are mostly a 2027 story
For smaller developers, the dossier shows a pattern of timelines stretching into next year, and in several cases the company itself supplies the date.
Scribe Therapeutics, listed on Nasdaq under the ticker SCTX, reported third-quarter results on 12 November 2026. It is enrolling a first-in-human trial of STX-1150, a gene-silencing therapy to lower LDL cholesterol, with initial clinical data expected in the first half of 2027.14 The company's case for the product is that current cholesterol drugs suffer from poor adherence, with studies showing 50% to 70% of patients discontinue within one year.14 It also points to people born with naturally occurring PCSK9 variants, who have been reported to have 28% lower mean LDL cholesterol and up to 88% lower coronary heart disease risk, and says STX-1150 aims to mimic that protection.14 These are company statements, not trial results. Scribe also says it expanded its collaboration with Sanofi, a partnership that matters because it provides validation and access beyond what a small company can fund alone.14
Ernexa Therapeutics says it remains on schedule to submit an application to begin human testing of ERNA-101 in the third quarter of 2026, with a first-in-human Phase 1 trial anticipated in the fourth quarter of 2026.15 Prelude Therapeutics expected an application for PRT13722 by mid-2026 and a Phase 1 study in ER-positive breast cancer in the second half of 2026.16 Akari Therapeutics, through its CEO, describes patients whose cancers no longer respond to current antibody drug conjugates as a growing unmet need and an exclusive opportunity for its novel payload, with Phase 1 development of AKTX-101 planned for mid-2027.17 Each of these is a plan stated by the company. None is a result.
The one clear piece of late-stage data in our files comes from Vor Bio. On 22 October 2026 it announced final two-year results from the Phase 3 TELIGAN trial of telitacicept in IgA nephropathy, a kidney disease. Annualized decline in kidney function was 0.6 versus 5.7 mL/min/1.73 m² per year for placebo, a difference of 5.1 (p<0.001), and risk of confirmed 30% and 40% declines in kidney function fell by 89% and 81% respectively.18 This is the company's own announcement, and independent review would be needed before drawing conclusions about how it compares with other treatments.
OPKO Health reported in July that its candidate OPK8801001 showed approximately 20-fold greater growth hormone receptor antagonism than the established drug Pegvisomant, in vitro.19 That is laboratory evidence only, and it has not been tested in patients.
The anchor: royalties from a drug already selling
The steadiest numbers in the dossier belong to a company that does not carry the development risk alone. BioArctic of Stockholm, which developed Leqembi and partners with Eisai, receives a royalty on its sales.20 Global Leqembi sales were 29.3 billion yen in the second quarter of 2026, producing a royalty to BioArctic of SEK 179 million, about 10 percent more than a year earlier.21 The comparison is flattered by a quirk: the prior year included a one-time stockpiling effect in China of around 5.3 billion yen. Excluding it, BioArctic says royalty revenue grew approximately 43 percent.21 Both figures are correct, and the gap between them is a useful reminder to ask which baseline a company is using.
We were asked to weigh large-cap demand, including Eli Lilly's weight-loss drugs. Our dossier contains only a Motley Fool comparison piece with no usable figures from it, so we make no claim about Lilly's numbers.
The AI-in-biology claims, and how well they have held up
Radical Numerics says AI-designed viruses have treated its first patient, with an experimental treatment targeting drug-resistant E. coli.22 That is a company claim relayed in a newsletter, and the dossier contains no outcome data.
Treat the source with care. MIT Technology Review items in our dossier have a measured reliability score of 6%: only 6% of 16 checked claims held up. That is a small sample and reflects mainly newsletter summaries, not the publication's full reporting, but it argues for caution. The same caution applies to Generation Lab, which describes its injectable treatment as one that, in its words, "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."23 That is a marketing description, supplied by the company, and the author of the article that reported it described himself as having been approached by the company. Nothing in our files tests it.
By comparison, the company press releases from which we draw most of the biotech claims above (labelled NewsEOD) score 54% across 6,692 checked claims. That is better but still means nearly half of checked claims did not hold up, and a press release is the company describing itself.
Our reading
Via News's analysis of this material is that the sector is splitting into two groups. Companies with products or royalties, such as Incyte and BioArctic, can absorb a jittery market. Companies promising first data in 2027 must reach it on money already raised or on partners such as Sanofi. Our files do not give cash runways for the smaller names, so we cannot say which of them are exposed. That gap is itself worth noting for any reader considering such shares.
What to watch
- Scribe's first clinical data for STX-1150, expected in the first half of 2027.14
- Ernexa's first-in-human start, anticipated in the fourth quarter of 2026.15
- Akari's planned Phase 1 start in mid-2027.17
- Incyte's next filing, to see whether cash, now about $3.28 billion, resumes its climb.10
- BioArctic's next royalty report, to see whether growth holds without a one-off boost.21

